Clinical trial · no report yet · Phase 3
NCT01272037
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
- NCT01272037 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 77 | |
| X threads | 61 | |
| Podcasts | 54 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Breast Ductal Carcinoma In Situ; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma
- Interventions
- Anastrozole; Exemestane; Laboratory Biomarker Analysis; Letrozole; Quality-of-Life Assessment; Systemic Chemotherapy; Tamoxifen Citrate
- Arms
- Arm I (chemotherapy and endocrine therapy) · Experimental
- Arm II (endocrine therapy) · Experimental
- Enrollment
- 5,018
- Primary outcomes
- Invasive Disease-Free Survival (IDFS)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Feb 28, 2011
- Primary completion
- Feb 1, 2023
- Results posted
- Yes
- Registry record
- NCT01272037 · updated Oct 22, 2026
Publications
linked from the registry- Abdou Y, Hoag J, Barlow WE, Albain KS, Gralow JR, Meric-Bernstam F, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Schott AF, Racz J, Baehner FL, Tripathy D, Hortobagyi GN, Pusztai L, Sharma P, Kalinsky K. Recurrence Score(R) gene group components and outcomes in the RxPONDER trial (SWOG S1007). J Natl Cancer Inst. 2026 Jul 15:djag221. doi: 10.1093/jnci/djag221. Online ahead of print. PubMed 42458791
- Kang IM, Forschmiedt JK, Loch MM, Lew DL, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Rastogi P, Schott AF, Baehner R, Sharma P, Tripathy D, Pusztai L, Hortobagyi GN, Kalinsky K, Henry NL. Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial. JAMA Oncol. 2026 Feb 1;12(2):159-166. doi: 10.1001/jamaoncol.2025.5220. PubMed 41379459
- Abdou Y, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Unger JM, Tripathy D, Hortobagyi GN, Pusztai L, Kalinsky K. Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial. J Natl Cancer Inst. 2025 May 1;117(5):889-897. doi: 10.1093/jnci/djae314. PubMed 39656951
- Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga JY, Bermejo B, Ramos-Vazquez M, Jung KH, Ferrero JM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Pusztai L, Hortobagyi GN. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med. 2021 Dec 16;385(25):2336-2347. doi: 10.1056/NEJMoa2108873. Epub 2021 Dec 1. PubMed 34914339